David Orr, DO
Pulmonary Disease · Hackensack, NJNPI 1215016217
Payments from drug & device makers
Across 765 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$3K
- Boehringer Ingelheim$1K
- Amgen$699
- Mylan Specialty L.p.$576
- Sanofi$561
- plus $5K from 33 others
What the payments were for
- Consulting fees$420%
- Food & beverage$13,78697%
- Education$3122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 72 | $3,444 |
| GSK | 215 | $2,752 |
| Boehringer Ingelheim | 96 | $1,301 |
| Amgen | 45 | $699 |
| Mylan Specialty L.p. | 34 | $576 |
| Sanofi | 34 | $561 |
| Regeneron Healthcare Solutions, Inc. | 24 | $561 |
| Grifols USA, LLC | 32 | $526 |
| Actelion Pharmaceuticals US, Inc. | 24 | $430 |
| Philips North America LLC | 23 | $334 |
| Genentech USA, Inc. | 17 | $322 |
| Novartis | 17 | $259 |
| Viatris Specialty LLC | 11 | $226 |
| Inspire Medical Systems, Inc. | 8 | $196 |
| Merck | 12 | $191 |
| Mallinckrodt Hospital Products Inc. | 6 | $178 |
| Insmed, Inc. | 11 | $174 |
| Sunovion Pharmaceuticals Inc. | 9 | $149 |
| Harmony Biosciences LLC | 9 | $148 |
| United Therapeutics Corporation | 9 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $140 |
| Teva Pharmaceuticals USA, Inc. | 9 | $121 |
| ANI Pharmaceuticals, Inc. | 6 | $94 |
| Intuitive Surgical | 1 | $89 |
| Pulmonx Corporation | 3 | $67 |
| Bayer | 4 | $54 |
| Verona Pharma, Inc. | 3 | $54 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $51 |
| Pfizer | 4 | $50 |
| ADMA Biomanufacturing LLC | 2 | $42 |
| Shire North American Group Inc | 3 | $42 |
| Jazz Pharmaceuticals Inc. | 2 | $31 |
| Johnson & Johnson | 2 | $27 |
| Baxter Healthcare | 1 | $25 |
| Lilly USA, LLC | 1 | $22 |
| EMD Serono, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $15 |
| Optinose US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,140 in reported general payments places this provider in the 85th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 491 | $398,883 |
| OfevNintedanib Esylate | 25 | $315,276 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 254 | $149,924 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $122,832 |
| Breo ElliptaFluticasone/Vilanterol | 200 | $104,767 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 102 | $88,289 |
| Spiriva RespimatTiotropium Bromide | 87 | $70,399 |
| Fasenra PenBenralizumab | 12 | $65,494 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 77 | $52,245 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 26 | $24,120 |
| SymbicortBudesonide/Formoterol Fumarate | 63 | $21,309 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 672 | $21,243 |
| EliquisApixaban | 20 | $20,162 |
| Arnuity ElliptaFluticasone Furoate | 34 | $11,863 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $11,589 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $2,752 | $676,8441,000 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,301 | $437,921189 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $3,444 | $133,718191 claims |
| Grifols USA, LLCProlastin C | $526 | $122,83213 claims |
| PfizerEliquis | $50 | $20,16220 claims |
| MerckDulera | $191 | $10,02818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Hackensack
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Emanuele SantomauroHackensack$420K
- Nadeem AliHackensack$133K
- Keith BrennerHackensack$42K
- John VillaHackensack$15K
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.